BioNexus Gene Lab (BGLC) announced that it has entered into a non-binding Strategic Partnership Term Sheet with BirchBioMed, a Canadian biopharmaceutical company developing regenerative treatments for organ fibrosis, topical scarring and autoimmune diseases. Under the non-binding term sheet, BGLC would lead Birch’s USD $10M upcoming financing round through a strategic equity investment and collaboration to accelerate commercialization of Birch’s FS2 topical platform in Southeast Asia. The partnership is designed to combine BGLC’s regional market access and infrastructure with Birch’s novel science in dermal regeneration and fibrosis control.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.